Can These 4 Biotech Penny Stocks Bring in the Bulls?
Biotech penny stocks have been on a big bull run since March of this year. With Covid on the rise around the world, investors are continuing to pay more attention to biotech stocks. Now, not all biotech stocks deal with Covid-related issues. But, the majority of biotech penny stocks can be correlated with one another.
This means that when one rises due to news or other events, we could see bull runs throughout the industry. Now, investors should also keep in mind that biotech penny stocks can be quite volatile. This means that there is potential for both big gains and equally big losses.
- Gold & Silver Penny Stocks to Watch During The Latest Correction
- Can You Make Money With Penny Stocks On Robinhood? 3 To Know Now
- Penny Stocks Under $1 To Watch This Week; 1 Analyst Sees 200% Upside
Regardless, if investors are willing to do the research, there are plenty of options for biotech penny stocks to watch. Investors should always make sure that they know both the financials of the company as its future plans. Because there are so many biotech penny stocks to watch, finding the right one can be challenging. But, with the internet at our fingertips, research is always an investors best friend. With this in mind, let’s take a look at four biotech penny stocks that could bring in the bulls.
Biotech Penny Stocks To Watch: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) is one of the immunotherapy penny stocks to watch this quarter. While a lot of the initial momentum built after a Dose Level 3 update in its Phase I/II GTB-3550 trial in September, October saw an additional surge. The company’s GTB-3550 is in trials for treatment of acute myeloid leukemia and this Dose level was well tolerated by the patient.
One of the bigger things to consider when it comes to GT Biopharma is the upcoming presentation at a major industry conference. Interim data was chosen for the American Society of Hematology Annual Meeting in a few weeks. What’s more is that the company’s treatment platform is being explored for even more indications. A recent research effort was conducted by researchers at the University of Minnesota and at Massachusetts General Hospital/Harvard Medical School. The focus was on utilizing a a B7H3-targeted TriKE™.
This B7H3 protein is expressed on different tumors and was found to have the potential to enhance natural killer cell immunotherapy in solid tumor settings. Based on the findings, the company expressed that it will advance a B7H3 TriKE™ product candidate to clinical development. Additionally, when you look at the chart, you might also see that GTBP stock has bounced multiple times off of its 200 day moving average, any time it tested this level, since July. Will that remain the case in November?
Biotech Penny Stocks to Watch: Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc. (TTNP Stock Report) is a biotech penny stock that shot up by almost 28% by EOD on November 10th. At the beginning of the month, the company announced that it had completed an agreement to settle its debt with Molteni and Horizon Credit. In addition, the company announced that it had agreed to acquire JT Pharmaceutical Inc’s drug known as JT-09 for use in combination with its drug ProNeura.
The executive chairman of the company, Dr. Marc Rubin stated that “as a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan’s assets, including all the ProNeura intellectual property. With the net proceeds from our recent public offering, a significant reduction in operating expenses, and full ability to capitalize on our IP, we are well-positioned to progress.”
Based out of California, Titan Pharmaceuticals has been working to develop its ProNeura drug to treat a wide range of chronic conditions. With shares at only $0.14 as of November 10th, it looks like TTNP stock has a low barrier to entry for investors. All things considered, it continues to look like an intriguing biotech penny stock to watch.
Biotech Penny Stocks to Watch: Heat Biologics Inc.
Heat Biologics Inc. (HTBX Stock Report) is a clinical-stage biopharmaceutical company working on the development of several immune system-based therapies. In addition to this, it is also working on several oncology based drugs as well as a Covid-19 vaccine. The vaccine it is working on is one of the reasons that the company has received so much attention. In the past six months, shares of HTBX stock have shot up by almost 75%. After hitting a high of $3.62 on July 20th, prices corrected down to the $1 mark as of November 10th.
Recently, the company announced its third quarter 2020 results. Jeff Wolf, CEO of Heat Biologics stated that “we continue to make progress on both our oncology and COVID-19 vaccine programs. We presented data for HS-110 in combination with Nivolumab in our Phase 2 lung cancer trial at the 2020 American Society of Clinical Oncology Annual Meeting demonstrating a strong survival benefit in a cohort of previously treated checkpoint inhibitor naive patients with advanced…cancer.”
What’s more important for investors in the present day is that the company is working on producing data for its gp96-based Covid-19 vaccine. The data has shown that the vaccine candidate produced a very strong immune response directly correlated to the Covid-19 virus. The company went on to state that “as a result, we believe that our vaccine has the potential to be used as either a standalone vaccine or in combination with other antibody-focused vaccine approaches to enhance prophylactic protection.”
As a Covid-related biotech stock, many investors have begun to focus on Heat Biologics. But, it remains up to individual investors to make a decision as to whether or not HTBX stock is right for them.
Biotech Penny Stocks to Watch: Trevena Inc.
Trevena Inc. (TRVN Stock Report) is an interesting biotech penny stock working on a variety of treatments. The company recently announced that it received approval from the FDA for its drug known as Oliceridine. With this, many believe that the company could see a greater amount of critical appeal.
To understand why this drug has gained so much interest, we can compare it to other IV received opioids. Currently, there are around 45 million patients that are given intravenous doses of opioids. The company states that if it is able to capture 9 million of those, it would give it a $1.5 billion market opportunity. While opioid use is highly criticized, the usage of this substance is limited only to hospitals and emergency situations. This means that the potential for abuse can be limited.
In addition to the U.S. market, the company is working on commercializing the drug in South Korea and China. This could be a major step for the company as it would give it access to a much broader consumer base than just the U.S. While analysts expect revenue to start on the slower side, the longer term is where the potential could lie for Trevena Inc.
On Tuesday, November 10th, shares of TRVN stock shot up by around 5% during intraday trading. This bullish momentum is something that we have seen in several of the past few trading days with TRVN stock. In the past six months, shares of TRVN stock are up by over 150%. With this solid momentum, it is up to investors to decide if TRVN is a penny stock to buy or sell.